Senator Mark Warner from the United States has raised concerns about the growing technological power of China, specifically highlighting the Beijing Genomics Institute (BGI). Warner mentioned that BGI, a genomics company, has the potential to surpass even the technology giant Huawei. Initially focused on a national genome project, BGI now commercializes its services, collecting DNA data from various sources globally for hospitals, pharmaceutical companies, and researchers in numerous countries.
The services offered by BGI range from DNA sequencing, prenatal testing, cancer screening, to large-scale genetic analysis. This accumulation of genetic data has raised national security concerns in the U.S., with intelligence officials warning about the vast genetic database accessible to BGI. The data gathered not only contains medical information but could also reveal ancestry, physical traits, disease risks, and family relationships.
Moreover, there are fears surrounding the possible military applications of genetic modifications, with concerns about the creation of super soldiers. Former Director of National Intelligence John Ratcliffe highlighted China’s research activities related to DNA collection, military databases, and AI-based human performance modeling. Warner drew parallels between Huawei’s early dominance in the market and BGI’s potential rise as a leading biotechnology company.
Warner criticized the U.S. intelligence community for overlooking the threats posed by biotechnology, emphasizing the need to prioritize commercial technologies in addition to foreign governments and militaries. The evolving landscape of biotechnology in China raises implications for national security, underscoring the importance of proactive measures to address potential risks associated with genetic data and advanced biotechnological advancements.
